Overslaan en naar de inhoud gaan

Highlights: 

  • Full year revenues from product sales were up over 51% on 2017 to €134.3 million, reflecting strong growth in both the USA and Europe. Including deferred license income, total revenues were €135.1 million (US$159.7 million) – an increase of almost 51% on 2017
  • Fourth quarter product sales of €36.7m (US$41.9 million) – as guided; in similar range to Q3 2018
  • 2018 US product sales triggered first $20 million milestone payment to Valeant, paid earlier this month
  • Full year net profits, including financing costs and non-cash adjustments, were €25.0 million 
  • Full year unadjusted operating profit (EBIT) of €40.6 million (US$48.0 million), before a non-cash adjustment to take previously capitalised development costs for a superseded new form of RUCONEST® through the income statement, resulting in a final figure of €38.0 million (US$44.9 million)
  • Cash ended at €81.5 million, an increase of €21.5 million versus year end 2017 
     

"We are confident that with our increasing patient reach and advancing pipeline, we will continue to deliver significant value to all our stakeholders.”

- Sijmen de Vries - CEO
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren